Opinion

Video

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)

Author(s):

Elizabeth R. Plimack, MD, MS, FASCO,Neeraj Agarwal, MD

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Related Videos
David A. Braun, MD, PhD
Bradley McGregor, MD,
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
Related Content
Qing Chen, MD, PhD
January 17th 2025

Fox Chase Cancer Center Welcomes Dr. Qing Chen

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Yousef Zakharia, MD, medical oncologist, vice chair, Genitourinary Malignancy Disease Group, Mayo Clinic Comprehensive Cancer Center; medical director, Experimental Therapeutics Clinic, Mayo Clinic
January 15th 2025

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Belzutifan Plus Cabozantinib in RCC | Image Credit: © Katsyarina - stock.adobe.com
January 9th 2025

First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC

lertsakwiman – stock.adobe.com
January 8th 2025

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer